27
total announcements
LALPATHLAB.NS · 15 min delayed
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has informed the Exchange about a copy of newspaper publication regarding unclaimed equity shares due for transfer to the Investor Education and Protection Fund (IEPF) and notice to shareholders for the 11th Annual General Meeting (AGM) of Digjam Limited.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has informed the Exchange about the completion of subscription of 30% stake in Neuome Technologies Private Limited by its wholly-owned subsidiary Dr. Lal Ventures Private Limited.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has incorporated a step-down subsidiary company, Dr. Lal PathLabs Indomed LLC, in Tashkent, Uzbekistan, with its wholly-owned subsidiary Dr. Lal PathLabs FZCO subscribing to 70% of its share capital.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has informed the Exchange regarding the allotment of 211050 shares under the Dr. Lal PathLabs Employee Stock Option Plan 2022. The paid-up equity share capital of the company has increased to INR 1,67,84,88,200 divided into 16,78,48,820 equity shares of INR 10/- each.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has informed the Exchange about the Transcript of Q1 & FY27 Earnings Conference Call. The company's revenue for Q1 FY27 was Rs. 798 crore, registering a year-on-year growth of 19.1%. The revenue growth is mainly driven by Patient volumes and sample volumes.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has informed the Exchange regarding Change in Director(s) of the company. Mr. Gurinder Singh Kalra has completed his current tenure as an Independent Director of the company on July 26, 2026, and consequently ceases to be an Independent Director of the company.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has submitted the Exchange a copy Scrutinizers report of the Annual General Meeting held on July 25, 2026. The company has informed the Exchange regarding voting results.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. held its 32nd Annual General Meeting on July 25, 2026, through video conferencing. The meeting was attended by 65 members, including 3 promoters and 62 public shareholders. The company's financial statements for the year ended March 31, 2026, were adopted, and a final dividend of INR 4 per share was declared. The remuneration structure of the executive chairman and whole-time director, (Hony) Brig Dr. Arvind Lal, was revised, and he was re-appointed for a five-year term. Dr. Vandana Lal's remuneration structure was also revised.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has informed the Exchange about the publication of a newspaper advertisement regarding its financial results for the quarter ended June 30, 2026.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has made the audio recording of its Q1 FY27 earnings conference call with investors and analysts available on its website.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation for Q1 FY2027 un-audited financial results.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has announced its un-audited financial results for the quarter ended June 30, 2026, with revenue increasing by 19.1% to Rs 798 Cr, EBITDA increasing by 28.7% to Rs 247 Cr, and PAT increasing by 27.2% to Rs 170 Cr. The company has also declared an interim dividend of 50% and has made two acquisitions.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has informed the Exchange regarding Grant of 119300 Stock Options, approved un-audited (Standalone & Consolidated) Financial Results for the Quarter ended June 30, 2026, declaration of Interim Dividend of INR 5/- per equity share, and acquisition of stakes in Sunshine Healthcare Limited and Neuome Technologies Private Limited.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has announced its unaudited financial results for the quarter ended June 30, 2026, and has also approved the acquisition of stakes in Sunshine Healthcare Limited and Neuome Technologies Private Limited through its subsidiaries.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has announced its record date for the purpose of dividend payment as July 30, 2026, and declared an interim dividend of INR 5 per equity share.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has announced its un-audited financial results for the quarter ended June 30, 2026, and approved an interim dividend of INR 5 per equity share. The company also approved the granting of stock options to eligible employees and noted the acquisition of stakes in Sunshine Healthcare Limited and Neuome Technologies Private Limited.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has declared an interim dividend of Rs. 5 per equity share, with a record date of July 30, 2026, and the dividend will be paid within 30 days of its declaration.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has announced its financial results for the quarter ended June 30, 2026, and approved an interim dividend of INR 5 per equity share. The company also approved the granting of stock options to eligible employees and noted the acquisition of stakes in Sunshine Healthcare Limited and Neuome Technologies Private Limited.
Dr. Lal Path Labs Ltd.
Dr. Lal Path Labs Ltd. has received an appellate order from the Income Tax Department, allowing their appeal and deciding in their favor, with the deduction on ESOP expenses of INR 32,66,18,927 being allowed.
Dr. Lal Path Labs Ltd.
Dr. Lal PathLabs Ltd. has informed the Exchange about Schedule of meet for Q1 FY27 earnings conference call on July 24, 2026.